Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones
Código 293750 (Harmonized System 2012 by 6 digits)
2023: US$2.78M, International Purchases
The states with the most international purchases in 2023 were Jalisco (US$2.47M), Ciudad de México (US$186k), and Estado de México (US$80.3k).
The main commercial origins of Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones in 2023 were South Korea (US$2.34M), Israel (US$143k), China (US$133k), United States (US$73k), and Italy (US$24.2k).
In the global context, the main exporting countries of Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones in 2022 were United States (US$63.1M), Czech Republic (US$62.8M), and Hungary (US$36.5M). In the same year, the main importing countries of Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones were Japan (US$47.6M), Germany (US$47M), and United States (US$33M).
Trade Balance of Mexico
#permalink to sectionNet Trade Balance
#permalink to sectionThe visualizations show the net balance of Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
Net International Trade
#permalink to sectionNovember, 2024: US$65.8k, International Purchases
In November 2024, international sales of Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones were US$0, while international purchases reached US$65.8k. The above results in a trade balance of -US$65.8k.
Exchange by Territory
#permalink to sectionInternational Purchases
#permalink to sectionJalisco: US$2.47M, State with the Most International Purchases (2023)
South Korea: US$2.34M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones were Jalisco (US$2.47M), Ciudad de México (US$186k), and Estado de México (US$80.3k).
The countries with the most international sales to Mexico in 2023 were South Korea (US$2.34M), Israel (US$143k), China (US$133k), United States (US$73k), and Italy (US$24.2k).
Specialization
#permalink to sectionSpecialization by State
#permalink to sectionThe RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
Global Market
#permalink to sectionOrigins and Trade Destinations
#permalink to section- 0.00014%, Mexican share in global exports - 2022
- 0.98%, Mexican share in global imports - 2022
The visualizations show the global market for Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones were United States (US$63.1M), Czech Republic (US$62.8M), and Hungary (US$36.5M). In the same year, the main importing countries for Prostaglandins, Thromboxanes and Leukotrienes, their Derivatives and Structural Analogues, Used Primarily as Hormones were Japan (US$47.6M), Germany (US$47M), and United States (US$33M).